Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383052
Status:
RECRUITING
Last Update Posted:
2024-04-25
First Post:
2024-04-17
Brief Title:
A Phase 12 Study of 177Lu-NYM032 Injection in mCRPC
Sponsor:
Norroy Bioscience Co LTD
Organization:
Norroy Bioscience Co LTD
Study Overview
Official Title:
A Phase 12 Study to Evaluate the Safety Pharmacokinetics Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen PSMA-expressing prostate tumors NYM032 is a small molecular with strong affinity for PSMA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None